tradingkey.logo

Castle Biosciences Inc

CSTL
查看詳細走勢圖
40.090USD
-0.110-0.27%
收盤 12/24, 13:00美東報價延遲15分鐘
1.17B總市值
虧損本益比TTM

Castle Biosciences Inc

40.090
-0.110-0.27%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.27%

5天

+1.08%

1月

+4.16%

6月

+109.24%

今年開始到現在

+50.43%

1年

+44.62%

查看詳細走勢圖

TradingKey Castle Biosciences Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Castle Biosciences Inc當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名9/206位。機構持股佔比非常高,近一個月多位分析師給出公司評級為強力買入。最高目標價37.75。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Castle Biosciences Inc評分

相關信息

行業排名
9 / 206
全市場排名
57 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 8 分析師
強力買入
評級
37.750
目標均價
-0.92%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Castle Biosciences Inc亮點

亮點風險
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
業績高增長
公司營業收入穩步增長,連續3年增長142.32%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值低估
公司最新PE估值-97.28,處於3年歷史低位
機構加倉
最新機構持股26.96M股,環比增加0.03%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉2.16M股
活躍度增加
近期活躍度增加,過去20天平均換手率0.95

Castle Biosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Castle Biosciences Inc簡介

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
公司代碼CSTL
公司Castle Biosciences Inc
CEOMaetzold (Derek J)
網址https://castlebiosciences.com/

常見問題

Castle Biosciences Inc(CSTL)的當前股價是多少?

Castle Biosciences Inc(CSTL)的當前股價是 40.090。

Castle Biosciences Inc 的股票代碼是什麼?

Castle Biosciences Inc的股票代碼是CSTL。

Castle Biosciences Inc股票的52週最高點是多少?

Castle Biosciences Inc股票的52週最高點是40.610。

Castle Biosciences Inc股票的52週最低點是多少?

Castle Biosciences Inc股票的52週最低點是14.590。

Castle Biosciences Inc的市值是多少?

Castle Biosciences Inc的市值是1.17B。

Castle Biosciences Inc的淨利潤是多少?

Castle Biosciences Inc的淨利潤為18.25M。

現在Castle Biosciences Inc(CSTL)的股票是買入、持有還是賣出?

根據分析師評級,Castle Biosciences Inc(CSTL)的總體評級為--,目標價格為37.750。

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是多少

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是-0.412。
KeyAI